Multiple ill-defined hypodense liver lesions (Figure 3) consistent with hepatocellular carcinoma with bilateral adrenal metastases (Figure 4).

CASE REPORT

A 61 year-old Malay male with underlying history of diabetes, hypertension and Hepatitis B presented with painless subcutaneous swelling in the scalp of 4 months duration. Physical examination revealed signs of chronic liver disease with multiple left supraclavicular lymphadenopathy. No hepatosplenomegaly. A well defined 14.0cm x 12.0cm swelling in the right parietal scalp which was firm in consistency and non tender was present. No pus discharge was noted from the swelling. His serum alpha fetoprotein was high (483.9 IU/mL). Skull radiograph followed by non contrast and contrasted computed tomography (CT) scan of the brain were done. Skull radiograph showed an osteolytic lesion in the right parietal bone (Figure 1). CT brain findings revealed soft tissue mass at the right parietal region with adjacent bony destruction (Figure 2). Subsequently, a percutaneous needle biopsy of the scalp lesion confirmed a metastasis from a multicentric hepatocellular carcinoma. A retrograde diagnostic work-up for detecting the primary cancer was then performed. An abdominal CT scan revealed multiple ill-defined hypodense liver lesions (Figure 3) consistent with hepatocellular carcinoma with bilateral adrenal metastases (Figure 4).

DISCUSSION

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and the most common primary malignant tumor of the liver. The major risk factor for HCC is Hepatitis C, evidenced by presence of antibody to HCV (anti-HCV) and HCV RNA. Other risk factors include liver cirrhosis due to long standing chronic hepatitis B, C, or hereditary hemochromatosis and other metabolic disorders. Patients with longstanding alcoholic cirrhosis are also at risk for developing this tumor. HCC spreads locally and metastasizes distally by hematogenous and lymphatic routes. The commonest site for spread of HCC is via invasion of the liver capsule followed by extra vascular invasion, vascular invasion and lastly by intrahepatic metastasis. It has been reported that extra-hepatic spreading of HCC is not uncommon and usually involve lymph nodes (42%), lungs (18%) and the adrenal gland.

This patient initially visited the hospital due to the incidentally discovered scalp mass. It is a similar presentation to the reported case by Latif A et al in 2002. From the previous literature, metastases from HCC is commonly present in the skull base and less
frequently seen in the skull vault with a subcutaneous mass as the most common clinical presentation (63%). Other signs and symptoms are neurological deficits (44%), headache (11%) and seizures.¹⁴ Patients who present with neurological deficits usually manifest as facial palsy, deafness, visual disturbance, facial numbness, weakness of limbs, and other cranial nerve palsies, depending on the size of tumor and its location.¹⁴

HCC rarely metastasizes to the bones.⁵,⁶ Such osseous metastases are mainly of the spine or long skeletal bones, and only 6% to the skull bones in autopsy cases.⁷ The incidence of intracranial metastases and/or skull metastases is extremely rare and assessed on the basis of postmortem studies. In all cases the plain skull radiograph appearance of the metastases was osteolytic.⁸

Recently, diagnosis is reached by neurological findings and imaging studies, such as CT and MRI because of improvements in these modalities. The metastatic lesions appeared as expansile osteolytic masses on CT and as hypervascular masses on angiography. On MR imaging, compared with the brain parenchyma, the lesions were iso- or hypointense on T1-weighted and T2-weighted MR images. The lesions were moderately to markedly enhanced by intravenous gadolinium-DTPA. The relatively hypointense tumor on T2-weighted MR images associated with flow void, different from primary skull tumors or directly invasive tumors may support the diagnosis of HCC metastasis.⁹

Hepatocellular carcinoma is an aggressive tumor and may be at an advanced stage when detected. Treatment of hepatocellular carcinoma may be directed towards a cure, or focused towards palliation. Recently, with the advances in non-surgical treatment of HCC worldwide, a number of therapies that offer good palliation can be chosen.⁹ Treatment options are dictated by the extent and stage of the tumor and functional reserve of the liver. Among them are percutaneous ablation including percutaneous ethanol injection therapy (PEIT), radiofrequency ablation (RFA) and transcatheter embolization. All of these methods can prolong the survival rate of the patient even in advanced cases of HCC. However, they have their particular indications, contraindications and complications.⁹

The prognosis for patients with HCC is so poor that treatment of such a distant metastatic lesion cannot be achieved before death occurs due to the primary malignancy. Therefore, the clinical manifestations of cranial metastasis prior to that of primary HCC have rarely been reported.⁹

As illustrated by this case, the diagnosis of HCC should be considered in the differential diagnosis of patients with subcutaneous scalp mass and osteolytic defects on radiograph especially in the patients with underlying cirrhosis. An isolated skull metastasis may be the sole initial presentation of HCC. Early diagnosis is essential in order to treat the primary disease. In conclusion, bone metastases from HCC are rare and it is even rarer to find bone metastases as the first overt manifestation of HCC.
Figure 1. Lateral skull X-ray showed an osteolytic lesion in the right posterior parietal bone (arrows).

Figure 2. Contrast enhanced CT of the brain showed a well defined enhancing soft tissue mass in the right posterior parietal region with bony destruction (arrows).
Figure 3. Contrast enhanced CT of abdomen showed multiple ill-defined area of heterogeneously hypodense lesion in both liver lobes with minimal enhancement on arterial phase (arrows).

Figure 4. CECT showed enlarged and lobulated right and left adrenal glands with minimal enhancement in keeping with adrenal metastases (arrows).
REFERENCES

1. Latif A, Muzrekchi A. Bone Metastasis Hepatocellular Carcinoma. QMJ 2002; 11(1)